2005
Managing HIV/AIDS in correctional settings
Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports 2005, 2: 165-170. PMID: 16343373, DOI: 10.1007/s11904-005-0011-9.Peer-Reviewed Original ResearchConceptsHIV/AIDSHIV care sitesActive antiretroviral therapyBurden of infectionEffective drug treatmentHIV risk behaviorsQuarter of peopleCorrectional health care systemIllicit drug useEffective case managementUntreated mental illnessHealth care systemPublic health officialsCorrectional settingsAntiretroviral therapyAdherence strategiesHIV outcomesComorbid conditionsManaging HIV/AIDSEffective therapyHIV epidemicHigh prevalenceCare sitesDrug treatmentHIV detection18 Management of HIVIAIDS in Correctional Settings
Altice F, Springer S. 18 Management of HIVIAIDS in Correctional Settings. 2005, 449-487. DOI: 10.1016/b978-012465271-2/50021-2.Peer-Reviewed Original ResearchClean injection equipmentHepatitis virus BHepatitis virus CPrevalence of HIVSelf-administered therapyArea of HIVSyringe exchange programsGeneral U.S. populationCorrectional settingsObserved therapyHIV infectionHIV medicationsComorbid conditionsMethadone maintenanceOwn medicationsSyringe exchangeNew casesVirus CCommunity settingsMedicationsHIVInformed consentExtensive involvementVirus BU.S. population
2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount